Author

T. Gade

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1 Assay:proteomics· 1 Organism:rat· 1

Frequent Co-Authors

A. Gurevich· 1 shared A. M. Zahm· 1 shared A. Vasquez-Salgado· 1 shared B. Furth· 1 shared D. Ackerman· 1 shared D. Kaplan· 1 shared D. Tischfield· 1 shared G. Nadolski· 1 shared

Activity by Year

2019-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Gurevich

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Transarterial embolization modulates the immune response within target and non-target hepatocellular carcinomas.

D. Tischfield, A. Gurevich, O. Johnson, I. Gayatman, G. Nadolski, D. Kaplan, B. Furth, S. Hunt, T. Gade

This study examines how transarterial embolization affects immune responses in both target and non-target hepatocellular carcinomas in a rat model.

bioRxiv · Nov 7, 2020 · PreprintImmunology

In vivo screen identifies LXR agonism potentiates sorafenib killing of hepatocellular carcinoma

M. E. Preziosi, A. M. Zahm, A. Vasquez-Salgado, D. Ackerman, T. Gade, K. H. Kaestner, K. J. Wangensteen

The paper identifies LXR agonism as a potential enhancer of sorafenib's efficacy in treating hepatocellular carcinoma through an in vivo genetic screen and mechanistic studies.

bioRxiv · Jun 13, 2019 · PreprintCancer Biology